Ivashkova Yulia, Svetnitsky Albert, Mayzler Olga, Pruneau Didier, Benifla Mony, Fuxman Yulia, Cohen Avi, Artru Alan A, Shapira Yoram
Division of Anesthesiology, Soroka Medical Center, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
J Trauma. 2006 Oct;61(4):879-85. doi: 10.1097/01.ta.0000234722.98537.01.
We evaluated the effect of LF 18-1505T, a novel nonpeptide bradykinin type-2 receptor antagonist, on brain edema and neurologic severity score (NSS) after closed head trauma (CHT).
There were 132 rats anesthetized and assigned for sham or CHT; infusion of saline or LF 18-1505T (0.3, 1, 3, 10, or 30 microg x kg x min); and determination of neurologic outcome (brain water content and NSS) or physiologic variables (blood pressure, glucose concentration, etc.).
Post-CHT brain water content was less with LF 18-1505T doses of 3 and 10 microg x kg x min (80.1 +/- 3.8 through 81.6 +/- 2.6%, mean +/- SD) than in the untreated group (84.6 +/- 1.9%, p < 0.01). Post-CHT NSS improved with doses of 3, 10, and 30 microg x kg x min (median, 7; range, 0-12 through median, 10; range, 8-18) as compared with that in the untreated group (median, 17; range, 14-23; p < 0.05). LF 18-1505T with or without CHT did not significantly alter physiologic variables.
LF 18-1505T decreased brain edema and improved neurologic status after CTH in rats without significantly altering physiologic values.
我们评估了新型非肽类缓激肽2型受体拮抗剂LF 18 - 1505T对闭合性颅脑损伤（CHT）后脑水肿和神经严重程度评分（NSS）的影响。
132只大鼠麻醉后分为假手术组或CHT组；输注生理盐水或LF 18 - 1505T（0.3、1、3、10或30微克·千克·分钟）；并测定神经功能结局（脑含水量和NSS）或生理变量（血压、血糖浓度等）。
CHT后，LF 18 - 1505T剂量为3和10微克·千克·分钟时（80.1±3.8至81.6±2.6%，平均值±标准差）的脑含水量低于未治疗组（84.6±1.9%，p<0.01）。与未治疗组相比（中位数为17；范围为14 - 23；p<0.05），CHT后NSS在剂量为3、10和30微克·千克·分钟时有所改善（中位数为7；范围为0 - 12至中位数为10；范围为8 - 18）。无论有无CHT，LF 18 - 1505T均未显著改变生理变量。
LF 18 - 1505T可减轻大鼠CTH后的脑水肿并改善神经功能状态，且未显著改变生理值。
